Clinical Observation On The CPT-11 Plus 5-FU For treatment Advanced Rectal Cancer
	    		
		   		
		   			
		   		
	    	
    	 
    	10.3760/cma.j.issn.1008-6706.2011.02.008
   		
        
        	
        		- VernacularTitle:伊立替康联合氟尿嘧啶治疗晚期直肠癌
 
        	
        	
        	
        		- Author:
	        		
		        		
		        		
			        		Weijun TANG
			        		
			        		;
		        		
		        		
		        		
			        		Hongyuan ZOU
			        		
			        		;
		        		
		        		
		        		
			        		Chunfang PENG
			        		
			        		
		        		
		        		
		        		
		        		
		        		
			        		
			        		
		        		
	        		
        		 
        	
        	
        	
        		- Publication Type:Journal Article
 
        	
        	
        		- Keywords:
        			
	        			
	        				
	        				
			        		
				        		Rectal neoplasms;
			        		
			        		
			        		
				        		Irinotecan;
			        		
			        		
			        		
				        		Fluorouracil;
			        		
			        		
			        		
				        		Chemotherapy
			        		
			        		
	        			
        			
        		
 
        	
            
            
            	- From:
	            		
	            			Chinese Journal of Primary Medicine and Pharmacy
	            		
	            		 2011;18(2):161-162
	            	
            	
 
            
            
            	- CountryChina
 
            
            
            	- Language:Chinese
 
            
            
            	- 
		        	Abstract:
			       	
			       		
				        
				        	Objective To evaluate the efficacy and adverse events of irinotecan (CPT-11) combined with 5-FU in treatment of patients with advanced rectal cancer. Methods 86 patients were randomly divided into FOLFIRI treatment group and IFL treatment group. The efficacy and adverse events were observed. Results There was no statistically significant difference between FOLFIRI treatment group and IFL treatment group in CR、PR、SD and RR(all P > 0. 05). There was also no statistically significant difference between FOLFIRI treatment group and IFL treatment group in adverse events(all P > 0.05). Conclusion Irinotecan in combination with 5-FU was effective and had some tolerable adverse events in treating patients with advanced rectal cancer in both FOLFIRI treatment group and IFL treatment group.